Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

During a scheduled visit to the anticoagulation clinic, a 67-year-old man with a mechanical mitral valve replacement undergoes point-of-care testing, which reveals an International Normalized Ratio (INR) of 7.4. He takes warfarin 5 mg daily, and his past INR results have consistently been well-controlled between 2.5 and 3.5. Four days ago, an urgent care physician prescribed a course of trimethoprim-sulfamethoxazole for acute cystitis. The patient notes that his dysuria has resolved. He explicitly denies experiencing hematuria, epistaxis, gingival bleeding, black tarry stools, or new bruising. Vital signs include a blood pressure of 128/78 mmHg and a heart rate of 76/min. Physical examination shows no evidence of petechiae, ecchymoses, or focal neurologic deficits.

Which of the following is the most appropriate next step in the management of this patient?

  1. Omit the next 1 to 2 doses of warfarin and recheck the International Normalized Ratio in 24 to 48 hoursAnswer
  2. B
    Administer oral phytonadione and withhold the next dose of warfarin
  3. C
    Administer four-factor prothrombin complex concentrate and intravenous phytonadione
  4. D
    Continue the current warfarin dose and immediately switch the antibiotic to nitrofurantoin
  5. E
    Order a non-contrast computed tomography scan of the head to rule out intracranial hemorrhage

Answer

Omit the next 1 to 2 doses of warfarin and recheck the International Normalized Ratio in 24 to 48 hours
The most appropriate next step in monitoring and treatment evaluation for this patient is to withhold the next 1 to 2 doses of warfarin and recheck the International Normalized Ratio (INR) in 24 to 48 hours. According to consensus guidelines, patients with an INR between 4.5 and 10.0 who exhibit no evidence of clinically significant bleeding should be managed by simply omitting 1 to 2 doses of warfarin. Routine use of vitamin K (phytonadione) is explicitly not recommended in this range due to the risk of over-reversal and subsequent thromboembolism, which is particularly dangerous in a patient requiring anticoagulation for a mechanical mitral valve (target INR 2.5 to 3.5). Once the INR approaches the therapeutic range, warfarin can be resumed at an adjusted dose.

Step-by-Step Solution

1
Evaluate the patient's current INR level and clinical bleeding status.
The patient has an INR of 7.4 with absolutely no signs or symptoms of clinical bleeding.
The presence of bleeding and the absolute INR value dictate the urgency and method of warfarin reversal.
2
Identify the etiology of the supratherapeutic INR.
The recent addition of trimethoprim-sulfamethoxazole.
Trimethoprim-sulfamethoxazole is a potent inhibitor of CYP2C9, which decreases warfarin metabolism and leads to a rapid increase in INR.
3
Apply evidence-based guidelines for managing a supratherapeutic INR without bleeding.
The correct management for an INR between 4.5 and 10.0 without bleeding is to withhold 1 to 2 doses of warfarin.
Routine administration of vitamin K is not recommended in this specific range because it risks over-correcting the INR and predisposing the patient to thromboembolic events, especially with a mechanical heart valve.

Key Concept

Management of supratherapeutic INR on warfarin therapy
Estimated Time:1m 15s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic